TTX-381
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TTX-381, covering 2025-12-18 to 2025-12-18. Get the full timeline:
Most recent: Clinical Trial Update: A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease [Phase 1, Phase 2]